The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetic parameters of gefitinib predicts its progression-free survival and adverse events.
Kosuke Mizoguchi
No relevant relationships to disclose
Yoichi Nakamura
No relevant relationships to disclose
Kazumi Sano
No relevant relationships to disclose
Yoji Ikegami
No relevant relationships to disclose
Kohei Motoshima
No relevant relationships to disclose
Shinnosuke Takemoto
No relevant relationships to disclose
Daiki Ogawara
No relevant relationships to disclose
Takaya Ikeda
No relevant relationships to disclose
Nanae Tomonaga
No relevant relationships to disclose
Hiroyuki Yamaguchi
No relevant relationships to disclose
Katsumi Nakatomi
No relevant relationships to disclose
Minoru Fukuda
No relevant relationships to disclose
Seiji Nagashima
No relevant relationships to disclose
Shigeru Kohno
No relevant relationships to disclose